Neith Business Summary

Neith Corp. (6236.TWO) operates a diversified business model that generates revenue through a combination of high-margin product sales and specialized service fees across the biotechnology and information security sectors. The company’s primary business segments include Healthcare & Wellness, which manufactures and distributes nutritional supplements (such as the King One and L-One brands), energy-based wellness products like Ganbanyoku stone spa beds, and genetic testing services. Its second major pillar is Information Security, managed through its subsidiary NeithNet, which provides threat intelligence, Managed Detection and Response (MDR), and network traffic analysis to enterprise clients. Neith Corp. competes primarily with specialized Taiwanese biotech and testing firms such as Level Biotechnology Inc. (3118.TWO), Bio Preventive Medicine Corp. (6810.TWO), and TCI GENE Inc. (6879.TWO), positioning itself as a niche integrated provider that bridges the gap between preventive healthcare technology and digital infrastructure security. As of March 2026, the company is led by Lin, Yueh-Feng, who serves as both Chairman and CEO, providing unified strategic direction for the firm’s multi-sector operations. Originally founded in October 1997 as Topro Technology Inc., an integrated circuit design house, the company underwent a significant strategic pivot and rebranding (formerly Come True Biomedical) to focus on the high-growth longevity and cybersecurity markets. The leadership team is supported by a board of directors with deep roots in Taiwan’s technology and financial sectors, overseeing a lean corporate structure of approximately 50 employees. Notable institutional interest remains focused on the company’s ability to leverage its legacy technical expertise in microcontrollers to enhance its modern portfolio of smart wellness devices and secure data platforms.